Study: Links between internalizing mental health symptoms and nicotine/tobacco use vary by gender identity among U.S. adolescents

Feb.27
Study: Links between internalizing mental health symptoms and nicotine/tobacco use vary by gender identity among U.S. adolescents
A study using 2020–2023 U.S. data from the ITC Youth Tobacco and Vaping Survey (ages 16–19) reports that both nicotine/tobacco use and internalizing mental health (IMH) symptoms vary across disaggregated gender identities, and that gender identity moderates the relationship between IMH symptoms and product use.

 

Key Takeaway

 

 

  • Data: U.S. arm of the ITC Youth Tobacco and Vaping Survey, 2020–2023, ages 16–19, n=28,959
  • Any current use prevalence: transgender girls ~29%, transgender boys ~24%, cisgender boys ~22%, cisgender girls ~19%, GNC ~14%
  • IMH symptom prevalence: GNC ~85%, transgender boys ~80%, cisgender girls ~67%, transgender girls ~65%, cisgender boys ~45%
  • Significant interaction between IMH symptoms and gender identity (p<0.0001)
  • Stratified results: IMH symptoms associated with broader use categories among cisgender boys; with noncombustible and dual use among cisgender girls; with higher noncombustible use among GNC youth; and with lower combustible/dual use in the combined transgender group

 


 

2Firsts, Feb 27, 2026 – 

 

According to a study published in LGBT Health, researchers examined how internalizing mental health (IMH) symptoms (depression/anxiety symptoms combined) relate to current nicotine/tobacco use among U.S. adolescents, and whether gender identity moderates this relationship. The analysis used the U.S. arm of the International Tobacco Control Youth Tobacco and Vaping Survey, a repeat cross-sectional online survey of adolescents aged 16–19 conducted from 2020 to 2023 (n=28,959). 

 

Current nicotine/tobacco use was categorized into four groups: no current use, exclusive combustible use, exclusive noncombustible use, and use of both product types. Gender identity was derived from current gender identity and sex assigned at birth, with transgender and gender nonconforming (GNC) identities presented separately. 

 

The report said prevalence of any current product use differed across gender identities, with transgender girls reporting the highest prevalence (about 29%), followed by transgender boys (about 24%), cisgender boys (about 22%), cisgender girls (about 19%), and GNC adolescents (about 14%). It also reported IMH symptom prevalence was highest among GNC adolescents (about 85%), followed by transgender boys (about 80%), cisgender girls (about 67%), transgender girls (about 65%), and cisgender boys (about 45%). 

 

The study reported significant interactions between IMH symptoms and gender identity (p<0.0001), and stratified analyses indicated that the strength and direction of associations between IMH symptoms and nicotine/tobacco use categories varied by gender identity. 

 

The authors concluded that disaggregating GNC and transgender identities is important for research on nicotine/tobacco use and mental health among adolescents. 

 

From a risk-structure perspective:

The study indicates that nicotine and tobacco use rates vary significantly across gender identity groups, with particularly high prevalence among transgender youth, alongside markedly elevated levels of internalizing mental health symptoms  . In addition, the statistically significant interaction between mental health symptoms and nicotine use (p < 0.0001)  suggests that vulnerability is not evenly distributed across populations. For the industry, this signals a potential shift in regulatory and public health framing—from product-centered risk discussions to subgroup-specific vulnerability assessments.

 

From a regulatory exposure perspective:

As research increasingly quantifies associations between mental health conditions and nicotine product use within specific demographic subgroups, regulators may incorporate more granular population impact assessments into product evaluations, marketing oversight, and youth access control policies. This could expand compliance expectations beyond product characteristics to include demographic risk considerations.

 

To understand the detailed contents of the study, please read the original article.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
China’s tobacco tax debate is moving from whether to raise prices to how the tax system should be designed. At a Beijing forum on World No Tobacco Day, experts discussed higher specific excise taxes, minimum tax burdens and dynamic adjustments linked to income and inflation. The issue also connects to China’s broader consumption tax reform, health financing and chronic disease costs. Public reports did not mention e-cigarettes, heated tobacco, nicotine pouches or other new nicotine products.
Jun.11
Product | VELO Launches Tomorrowland Limited Edition 2026 as Festival IP Enters Nicotine Pouch Packaging
Product | VELO Launches Tomorrowland Limited Edition 2026 as Festival IP Enters Nicotine Pouch Packaging
BAT’s nicotine pouch brand VELO has introduced the Tomorrowland Limited Edition 2026. Public retail-channel information shows the product has appeared across multiple European online platforms, while Haypp UK has listed related SKUs with a “Coming soon” status. The packaging carries the wording “Official Tomorrowland Partner,” indicating that the collection is part of VELO’s official collaboration with the electronic music festival brand.
Jul.02
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
The U.S. Food and Drug Administration (FDA) has issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products, allowing the already-authorized products to be marketed with a specific claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Jul.01
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
According to public records from China’s National Intellectual Property Administration, a patent application filed by China Tobacco Yunnan Industrial Co., Ltd. for “cigar flavor granules” was published on May 12, 2026. The filing proposes purifying an ethanol extract of cigar tobacco leaves using LX-8 macroporous resin, followed by encapsulation with maltodextrin and sucrose fatty acid ester to improve smoking comfort, reduce dryness and enhance aroma release stability in reconstituted tobacco.
Jun.10
BAT Estimates U.S. Unauthorized Vape Market at $9.4 Billion, Plans New Vuse and Velo Launches After FDA Enforcement Shift
BAT Estimates U.S. Unauthorized Vape Market at $9.4 Billion, Plans New Vuse and Velo Launches After FDA Enforcement Shift
British American Tobacco (BAT) CEO Tadeu Marroco said the U.S. unauthorized vape market is worth about £7 billion, or US$9.43 billion. Following a shift in FDA enforcement policy, BAT plans to launch flavored Vuse products in the third quarter and an updated Velo pouch in August or September.
Jun.15